1型铜绿假单胞菌高分子量多糖疫苗的安全性和免疫原性。
Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.
作者信息
Pier G B
出版信息
J Clin Invest. 1982 Feb;69(2):303-8. doi: 10.1172/jci110453.
Abstract
The safety and immunogenicity of a high molecular weight polysaccharide from immunotype 1 Pseudomonas aeruginosa were tested in a dose response fashion in adult volunteers. The vaccine lacked toxicity and pyrogenicity for experimental animals. Doses of 50, 75, 150, or 250 microgram were given to groups of individuals as a single dose subcutaneous injection. Doses of 150 and 250 microgram were associated with a significant rise in binding and opsonic antibody at 2 wk postimmunization. Titers remained unchanged for up to 6 mo. The vaccine was almost devoid of toxicity, eliciting no more than a slightly sore and tender arm at the site of injection. High molecular weight polysaccharide antigen appears to induce a good immune response following vaccination that is effective in mediating opsonophagocytic killing of live P. aeruginosa organisms.
摘要
在成年志愿者中以剂量反应方式测试了1型铜绿假单胞菌高分子量多糖的安全性和免疫原性。该疫苗对实验动物无毒性和致热原性。将50、75、150或250微克剂量作为单剂量皮下注射给予不同组的个体。150和250微克剂量在免疫后2周时与结合抗体和调理素抗体的显著升高相关。滴度在长达6个月内保持不变。该疫苗几乎没有毒性，仅在注射部位引起手臂轻微疼痛和压痛。高分子量多糖抗原在接种疫苗后似乎能诱导良好的免疫反应，有效地介导对活铜绿假单胞菌的调理吞噬杀伤作用。
相似文献
1
Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.1型铜绿假单胞菌高分子量多糖疫苗的安全性和免疫原性。
J Clin Invest. 1982 Feb;69(2):303-8. doi: 10.1172/jci110453.
2
Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.铜绿假单胞菌免疫型2高分子量多糖的结构分析与免疫原性
J Clin Invest. 1986 Feb;77(2):491-5. doi: 10.1172/JCI112328.
3
Isolation, structure, and immunogenicity of Pseudomonas aeruginosa immunotype 4 high-molecular-weight polysaccharide.铜绿假单胞菌免疫型4高分子量多糖的分离、结构及免疫原性
Infect Immun. 1989 Feb;57(2):426-31. doi: 10.1128/iai.57.2.426-431.1989.
4
Polysaccharide antigens of Pseudomonas aeruginosa.铜绿假单胞菌的多糖抗原
Rev Infect Dis. 1988 Jul-Aug;10 Suppl 2:S337-40. doi: 10.1093/cid/10.supplement_2.s337.
5
Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa.人对铜绿假单胞菌多糖疫苗免疫反应的特征分析
J Infect Dis. 1983 Aug;148(2):206-13. doi: 10.1093/infdis/148.2.206.
6
Immunologic basis for mouse protection provided by high-molecular-weight polysaccharide from immunotype 1 Pseudomonas aeruginosa.1型铜绿假单胞菌高分子量多糖对小鼠的保护作用的免疫学基础。
Rev Infect Dis. 1983 Nov-Dec;5 Suppl 5:S957-62. doi: 10.1093/clinids/5.supplement_5.s957.
7
Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans.一种多价铜绿假单胞菌O-多糖-毒素A疫苗在人体中的安全性和免疫原性。
Antibiot Chemother (1971). 1989;42:177-83. doi: 10.1159/000417618.
8
Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.源自铜绿假单胞菌的七价高分子量O-多糖疫苗的免疫原性和抗原性
Infect Immun. 1994 Sep;62(9):3608-16. doi: 10.1128/iai.62.9.3608-3616.1994.
9
Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.铜绿假单胞菌多糖-破伤风类毒素结合疫苗：人体安全性和免疫原性
J Infect Dis. 1986 Oct;154(4):682-8. doi: 10.1093/infdis/154.4.682.
10
O-polysaccharide-protein conjugates induce high levels of specific antibodies to Pseudomonas aeruginosa immunotype 3 lipopolysaccharide.O-多糖-蛋白质结合物可诱导机体产生高水平的针对铜绿假单胞菌3型免疫型脂多糖的特异性抗体。
Vaccine. 1987 Mar;5(1):33-8. doi: 10.1016/0264-410x(87)90006-5.
引用本文的文献
1
Understanding -Host Interactions: The Ongoing Quest for an Efficacious Vaccine.理解宿主相互作用：寻求有效疫苗的持续探索。
Cells. 2020 Dec 5;9(12):2617. doi: 10.3390/cells9122617.
2
Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous Strains Based on Expression Profiling of Outer Membrane Proteins During Infection.基于感染过程中外膜蛋白表达谱构建针对脂多糖-异源株的保护性疫苗。
Front Immunol. 2018 Jul 26;9:1737. doi: 10.3389/fimmu.2018.01737. eCollection 2018.
3
Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.铜绿假单胞菌脂多糖：一种主要的毒力因子、炎症引发剂及有效免疫的靶点。
Int J Med Microbiol. 2007 Sep;297(5):277-95. doi: 10.1016/j.ijmm.2007.03.012. Epub 2007 Apr 27.
4
Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model.用表达铜绿假单胞菌O抗原的鼠伤寒沙门氏菌对BALB/c小鼠进行口服疫苗接种，可提高急性致死性肺炎模型中的存活率。
Infect Immun. 2004 Dec;72(12):7012-21. doi: 10.1128/IAI.72.12.7012-7021.2004.
5
Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant.用减毒活aroA缺失突变体经鼻腔免疫小鼠后对致死性铜绿假单胞菌肺炎的保护作用。
Infect Immun. 2003 Mar;71(3):1453-61. doi: 10.1128/IAI.71.3.1453-1461.2003.
6
Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine.铜绿假单胞菌aroA基因缺失减毒活突变株的构建与鉴定作为鼻内疫苗候选物
Infect Immun. 2002 Mar;70(3):1507-17. doi: 10.1128/IAI.70.3.1507-1517.2002.
7
Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.源自含有百万碱基对人类免疫球蛋白基因座的转基因小鼠的抗铜绿假单胞菌脂多糖人单克隆抗体具有调理作用，可保护机体免受致命性铜绿假单胞菌败血症的侵害。
Infect Immun. 2001 Apr;69(4):2223-9. doi: 10.1128/IAI.69.4.2223-2229.2001.
8
Pseudomonas aeruginosa phage lysate as an immunobiological agent. 1. Selection of Pseudomonas aeruginosa clinical strains for phage lysate preparation.铜绿假单胞菌噬菌体裂解物作为一种免疫生物制剂。1. 用于制备噬菌体裂解物的铜绿假单胞菌临床菌株的选择。
Folia Microbiol (Praha). 1999;44(1):93-7. doi: 10.1007/BF02816229.
9
Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.铜绿假单胞菌杂交外膜蛋白F-I疫苗在人类志愿者中的安全性和免疫原性。
Infect Immun. 1999 Mar;67(3):1461-70. doi: 10.1128/IAI.67.3.1461-1470.1999.
10
Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains.小鼠对从铜绿假单胞菌O2血清型菌株中分离出的变异高分子量O多糖的复杂血清学和免疫反应。
Infect Immun. 1998 Aug;66(8):3719-26. doi: 10.1128/IAI.66.8.3719-3726.1998.
本文引用的文献
1
Agar-Gel Precipitating Antibody in Pseudomonas aeruginosa Infections.绿脓假单胞菌感染中的琼脂凝胶沉淀抗体。
Infect Immun. 1970 Oct;2(4):495-503. doi: 10.1128/iai.2.4.495-503.1970.
2
3
High-molecular-weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2.来自铜绿假单胞菌免疫型2的高分子量多糖抗原。
Infect Immun. 1981 Nov;34(2):461-8. doi: 10.1128/iai.34.2.461-468.1981.
4
Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients.烧伤患者使用假单胞菌免疫球蛋白和疫苗的对照试验。
Lancet. 1980 Dec 13;2(8207):1263-5. doi: 10.1016/s0140-6736(80)92334-x.
5
Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.人类对铜绿假单胞菌的免疫力。II. 热稳定调理素与型特异性脂多糖之间的关系。
J Infect Dis. 1972 Sep;126(3):277-87. doi: 10.1093/infdis/126.3.277.
6
Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors.人类对铜绿假单胞菌的免疫力。I. 细菌、多形核白细胞和血清因子的体外相互作用。
J Infect Dis. 1972 Sep;126(3):257-76. doi: 10.1093/infdis/126.3.257.
7
Type-specific immunity in pseudomonas diseases.假单胞菌病中的型特异性免疫。
J Lab Clin Med. 1972 Jan;79(1):47-54.
8
Advances in the management of Pseudomonas aeruginosa infections in cancer patients.癌症患者铜绿假单胞菌感染管理的进展
Eur J Cancer (1965). 1973 Jun;9(6):435-41. doi: 10.1016/0014-2964(73)90108-4.
9
Pseudomonas aeruginosa vaccine in cancer patients.癌症患者中的铜绿假单胞菌疫苗。
Ann Intern Med. 1973 Oct;79(4):518-27. doi: 10.7326/0003-4819-79-4-518.
10
Immunization against Pseudomonas in infection after thermal injury.烧伤后感染中针对铜绿假单胞菌的免疫接种。
J Infect Dis. 1974 Nov;130 Suppl(0):S152-8. doi: 10.1093/infdis/130.supplement.s152.
Zotero 插件